Sign in Subscribe
Diseases

Enhanced MRD Detection in BCP-ALL using Standardized 12-Color Flow Cytometry

Strategic Insights

— 1 min read

A breakthrough study published in the journal HemaSphere has demonstrated the effectiveness of a 12-color flow cytometric Minimal Residual Disease (MRD) protocol in detecting B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL). This new protocol, developed by the EuroFlow Consortium, expands on the existing 8-color flow cytometric MRD protocol and includes additional B-cell markers and exclusion T/NK-cell markers. The study aimed to improve MRD detection, particularly for patients treated with CD19-targeted therapies.

Key Takeaways:

  • The 12-color panel performs comparably to the 8-color BCP-ALL MRD panel, including both CD19-positive and CD19-negative cases.
  • The 12-color panel offers an improved definition of the B-cell lineage, particularly for expert-guided manual data analysis.
  • The new protocol incorporates additional B-cell markers and exclusion T/NK-cell markers, enhancing MRD detection.
  • The study evaluated 237 diagnostic BCP-ALL samples and 101 patient follow-up samples, demonstrating excellent concordance with molecular MRD levels (R2 = 0.88).
  • The new panel demonstrates good reproducibility and is compatible with the previously developed 8-color automated gating and identification (AGI) tool.
  • The EuroFlow Consortium previously developed an 8-color flow cytometric MRD protocol, effective for 98% of BCP-ALL patients treated with chemotherapy.
  • This study aims to enhance MRD detection, particularly for patients treated with CD19-targeted therapies.

Statistics:

  • 237 diagnostic BCP-ALL samples were evaluated in the study.
  • 101 patient follow-up samples were used to demonstrate the clinical validation of the new panel.
  • The 12-color BCP-ALL MRD tubes demonstrated excellence concordance with molecular MRD levels (R2 = 0.88).
  • The 8-color BCP-ALL MRD panel was effective for 98% of BCP-ALL patients treated with chemotherapy.

Sources:

  • Verbeek, M. W. C., et al. Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study. HemaSphere, 2025, 9(4), n/a–n/a. (HemaSphere – http://www.hemaspherejournal.com)
  • NewsRx. Reports Summarize Acute Lymphoblastic Leukemia Study Results from Erasmus University Medical Center (Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized ...). Hematology Week. May 12, 2025; p 4741.

Read more